<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245281</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16014</org_study_id>
    <nct_id>NCT03245281</nct_id>
  </id_info>
  <brief_title>LINQ for impEdance meAsuremeNt While Off From HF Medication Study</brief_title>
  <acronym>LEAN HF</acronym>
  <official_title>LINQ for impEdance meAsuremeNt While Off From HF Medication Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic BRC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-randomized, cross-over, unblinded, single-center feasibility study is
      to assess the sensitivity of the LINQ ICM to measure derived-subcutaneous impedance in
      patients with heart failure during periods when diuretics and/or HF-medication consumption is
      increased or suspended for 48 hours (up to 72 hours at physician discretion) and to collect
      safety information related to HF status and to medication consumption changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 30 subjects with a clinical diagnosis of Heart Failure will be enrolled in the study.
      It is expected that the subjects will be enrolled over a period of approximately 6 months.

      3 follow up visits are planned at 2, 4 and 6 months (+/- one week) following the LINQ ICM
      implant.

      The total expected duration of the study is of about 1 year. According to the enrolment
      chronological order, each subject will be allocated to Diuretic Suspension group (DS),
      Diuretic Increase (DI) or Diuretic+MRA medication Suspension (DMS), which will define the
      medication regimen before the follow-up visit.

      Primary objective of the study is detecting the variation of impedance magnitude and the time
      of occurrence after medication regimen changes will be evaluated at each follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>According to the enrolment chronological order, each subject will be allocated to Diuretic Suspension group (DS), Diuretic Increase (DI) or Diuretic+MRA medication Suspension (DMS), which will define the medication regimen before the follow-up visit.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Derived-subcutaneous impedance</measure>
    <time_frame>2 months</time_frame>
    <description>The variation of impedance magnitude and the time of occurrence after medication regimen changes will be detected by the LINQ ICM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>All AEs related to changes in the therapeutic regimen and/or to HF status will be collected through CRF completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Transitory Arrhythmias</measure>
    <time_frame>6 months</time_frame>
    <description>Any transitory arrhythmias related to drug regimen changes and/or HF condition will be collected through CRF completion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Diuretic Suspension (DS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diuretic Increase (DI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diuretic and Medication Suspension (DMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretic Suspension (DS)</intervention_name>
    <description>Stop diuretic consumption in the 48h before the follow-up visit</description>
    <arm_group_label>Diuretic Suspension (DS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretic Increase (DI)</intervention_name>
    <description>Double diuretics dosage in the 48h before the follow-up visit</description>
    <arm_group_label>Diuretic Increase (DI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretic and Medication Suspension (DMS)</intervention_name>
    <description>Stop diuretic and MRA medication consumption in the 48h before the follow-up visit</description>
    <arm_group_label>Diuretic and Medication Suspension (DMS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Diagnosis of Heart Failure

          -  Plasma NT-proBNP (&gt;250ng/L in SR and &gt;1,000ng/L in AF)

          -  LVEF &lt;50% measured in the year before enrolment

          -  Treated routinely with a daily dose of loop diuretic

          -  Receiving other guideline-indicated therapy for heart failure

          -  Willing to sign the informed consent form.

          -  Greater than 18 years of age.

        Exclusion Criteria:

          -  Pregnant patients (all females of child-bearing potential must have a negative
             pregnancy test before LINQ ICM implant)

          -  eGFR &lt;30 ml/minute.

          -  Any concomitant condition which in the opinion of the investigator would not allow a
             safe participation in the study.

          -  Patients with implanted pacemakers or defibrillators

          -  Severe aortic or mitral valve disease

          -  Breathlessness at rest or on minor exertion.

          -  Chest pain at rest or on mild or moderate exertion.

          -  Patients deemed too unstable to miss 48 hours of heart failure treatment

          -  Enrolled in another study that could confound the results of this study, without
             documented pre-approval from Medtronic study manager
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Cleland, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>NHS GREATER GLASGOW &amp; CLYDE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teodora Bellone</last_name>
    <phone>433566566</phone>
    <phone_ext>0031</phone_ext>
    <email>teodora.bellone@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mirko De Melis</last_name>
    <email>mirko.de.melis@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nhs Greater Glasgow &amp; Clyde</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Murphy, Dr</last_name>
      <email>claremurphy4@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29;117(4):e25-146. Epub 2007 Dec 17. Erratum in: Circulation. 2010 Jul 6;122(1):e10. Kissela, Bret [corrected to Kissela, Brett].</citation>
    <PMID>18086926</PMID>
  </reference>
  <reference>
    <citation>Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487-97. Review.</citation>
    <PMID>16079372</PMID>
  </reference>
  <reference>
    <citation>Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004 Jun 2;43(11):2036-43.</citation>
    <PMID>15172409</PMID>
  </reference>
  <reference>
    <citation>Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med. 1994 Feb 28;154(4):433-7.</citation>
    <PMID>8117176</PMID>
  </reference>
  <reference>
    <citation>Mittal S, Sanders P, Pokushalov E, Dekker L, Kereiakes D, Schloss EJ, Pouliot E, Franco N, Zhong Y, DI Bacco M, Pürerfellner H. Safety Profile of a Miniaturized Insertable Cardiac Monitor: Results from Two Prospective Trials. Pacing Clin Electrophysiol. 2015 Dec;38(12):1464-9. doi: 10.1111/pace.12752. Epub 2015 Oct 20.</citation>
    <PMID>26412309</PMID>
  </reference>
  <reference>
    <citation>Pürerfellner H, Sanders P, Pokushalov E, Di Bacco M, Bergemann T, Dekker LR; Reveal LINQ Usability Study Investigators. Miniaturized Reveal LINQ insertable cardiac monitoring system: First-in-human experience. Heart Rhythm. 2015 Jun;12(6):1113-9. doi: 10.1016/j.hrthm.2015.02.030. Epub 2015 Feb 26.</citation>
    <PMID>25728756</PMID>
  </reference>
  <reference>
    <citation>van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non-compliance in patients with heart failure; how can we manage it? Eur J Heart Fail. 2005 Jan;7(1):5-17. Review.</citation>
    <PMID>15642526</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

